## Synthetic Methods

DOI: 10.1002/ange.201206024

## Direct Copper-Catalyzed α-Arylation of Benzyl Phenyl Ketones with Aryl Iodides: Route towards Tamoxifen\*\*

Grégory Danoun, Anis Tlili, Florian Monnier, and Marc Taillefer\*

The direct and simple transition-metal-catalyzed  $\alpha$ -arylation of ketone enolates is the most general and efficient strategy to access compounds possessing a benzylic carbonyl moiety. This methodology thus constitutes an indispensable tool for the organic chemist, as the molecules obtained are often structural motifs of prime importance in pharmaceutical, agrochemical, or fine chemistry. The first example of such direct  $\alpha$ arylation was reported in the early 1970s by Semmelhack et al., who described an intramolecular nickel-catalyzed αarylation serving as a key step of the total synthesis of the cephalotaxinone.[1] Twenty years later there was a breakthrough in this field with the independant discovery of practical and efficient palladium-based catalysts by the groups of Miura, [2] Buchwald, [3] and Hartwig. [4] These elegant systems proved their efficiency in the intermolecular coupling of aryl halides with enolates generated in situ from the corresponding ketones in basic conditions. Since then, the  $\alpha$ arylation of ketones based on palladium, mainly associated with phosphines, [5] but also with other ligands such as Nheterocyclic carbenes<sup>[6]</sup> or cyclic alkyl aminocarbenes,<sup>[7]</sup> has been investigated. [8,9] Various types of ketones have been used with palladium systems and among them are cyclic ketones, dialkyl- or alkylaryl(or heteroayl) ketones, or aryl benzyl ketones.<sup>[8,9]</sup> Notably, the challenge of the selective mono αarylation of acetone was recently performed by Stradiotto et al.<sup>[10]</sup> and Ackermann et al.<sup>[11]</sup> in the presence of palladium/ phosphine systems. However, although palladium catalysis remains the method of choice, it suffers from several shortcomings, particularly from the perspective of its use in commercial syntheses because of the high cost, toxicity of the metal, and the necessity of using expensive ligands.

As part of our studies on copper-catalyzed arylation of nuclophiles, [12] we report herein the first efficient method for which the direct  $\alpha$ -arylation of a non-activated or non-protected family of enolizable ketones (the deoxybenzoin derivatives) with simple aryl iodides can also be achieved using a copper-based catalytic system, [13] wherein the less toxic and inexpensive metal is used together with 1,10-phenanthroline or diketone-type ligands. [14] The potential of the method is illustrated by its application in the total

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/anie.201206024.

synthesis of tamoxifen, the world's most-prescribed drug for treatment of breast cancer.

First, a set of experiments was performed using 4-iodotoluene and deoxybenzoin as model substrates. The latter and its derivatives constitute the ketone family of choice in this study, as their structure is present in numerous bioactive compounds. [15,16] The preliminary survey, carried out at 110 °C with various solvents, bases, and copper sources, helped us to evaluate the most efficient catalytic system for the desired transformation (Table 1). When copper iodide

**Table 1:** Copper-catalyzed  $\alpha$ -arylation of deoxybenzoin with 4-iodotoluene in the presence of 1,10-phenantroline (L1): parametric study. [a]

Entry	Solvent	[Cu]	Base	Yield [%] <sup>[b]</sup>
1	DMF or CH <sub>3</sub> CN	Cul	Cs <sub>2</sub> CO <sub>3</sub>	10
2	DMA	Cul	Cs <sub>2</sub> CO <sub>3</sub>	17
3	tBuOH	Cul	Cs <sub>2</sub> CO <sub>3</sub>	52
4	1,4-dioxane	Cul	Cs <sub>2</sub> CO <sub>3</sub>	70
5	1,4-dioxane	-	Cs <sub>2</sub> CO <sub>3</sub>	0
6	1,4-dioxane	Cul	Et <sub>3</sub> N or CsOH	0
7	1,4-dioxane	Cul	KOAc or K <sub>3</sub> PO <sub>4</sub>	3
8	1,4-dioxane	Cul	$Rb_2CO_3$ or $K_2CO_3$	20
9	1,4-dioxane	[Cu(acac) <sub>2</sub> ]	Cs <sub>2</sub> CO <sub>3</sub>	30
10	1,4-dioxane	Cu(OTf) <sub>2</sub> or Cu <sub>2</sub> O	Cs <sub>2</sub> CO <sub>3</sub>	44
11	1,4-dioxane	CuCl, Cu(OAc) <sub>2</sub> , CuBr <sub>2</sub> , or CuCN	Cs <sub>2</sub> CO <sub>3</sub>	50

[a] Reactions performed on 1 mmol scale (ketone/Arl = 1.5:1).<sup>[b]</sup> Yield determined by <sup>1</sup>H NMR spectroscopy using 1,3-dimethoxybenzene as an internal standard. acac = acetylacetonate, Tf = trifluoromethansulfonyl.

(10 mol %), 1,10-phenantroline (**L1**; 10 mol %), and  $Cs_2CO_3$  were used in solvents such as N,N'-dimethylformamide (DMF), acetonitrile (CH $_3$ CN), or dimethyacetamide (DMA), we observed for the first time the expected  $\alpha$ -arylated product **1** in low yield (Table 1, entries 1 and 2). The first significant result was obtained when the reaction was performed in *tert*-butyl alcohol, as 52 % of **1** was detected under these reaction conditions (Table 1, entry 3). Moreover, we were pleased to find that this yield could reach a satisfying value (70%) when 1,4-dioxane was used instead of tBuOH (Table 1, entry 4). Under these reaction conditions, replacing  $Cs_2CO_3$  by several organic and inorganic bases only led to

<sup>[\*]</sup> Dr. G. Danoun, Dr. A. Tlili, Dr. F. Monnier, Dr. M. Taillefer Institut Charles Gerhardt Montpellier, ENSCM 8 rue de l'Ecole Normale, 34296 Montpellier Cedex 5 (France) E-mail: marc.taillefer@enscm.fr

<sup>[&</sup>lt;sup>+</sup>] These authors contributed equally to this work.

<sup>[\*\*]</sup> The CNRS, ENSCM, and ANR (grant ANR-07-CP2D-08,  $\rm H_2OFERCAT$ ) are thanked for financial support.



disappointing results (Table 1, entries 6–8). Additionally, several different copper sources (oxidation state I or II) were screened but only low to modest conversions were detected even in the most favorable cases (Table 1, entries 9–11). It is worth noting that the blank experiments showed that the presence of the copper catalyst is necessary in our protocol (Table 1, entry 5).

We then examined, either in tBuOH or in 1,4-dioxane, the influence of the ligand upon the course of the reaction (Table 2). Diamine (**L5**, **L6**) and  $\beta$ -diketone (**L7**, **L8**, **L9**)

**Table 2:** Copper-catalyzed  $\alpha$ -arylation of deoxybenzoin with 4-iodotoluene in 1,4-dioxane or tBuOH using the ligands L.[a]

L		Yield [%] <sup>[b]</sup> in		L	L		Yield [%] <sup>[b]</sup> in	
		1,4- dioxane				1,4- dioxane		
-		8	6	, N , NH	L5	29	5	
N=	L1	70	52	, N , N	L6	23	8	
	L2	27	46		L7	20	17	
O <sub>2</sub> N N	L3	3	47		L8	24	58	
$\overset{Ph}{\underset{=N}{\bigvee}}\overset{Ph}{\underset{N=}{\bigvee}}$	L4	68	84	O O Ph	L9	11	8	

[a] Reactions performed on 1 mmol scale (ketone/ArI = 1.5:1). [b] Yields determined by  $^1$ H NMR spectroscopy using 1,3-dimethoxybenzene as an internal standard.

ligands were ineffective, except for  $\beta$ -acetylcyclohexanone (**L8**) in tBuOH (58% yield of **1**). Finally, the 1,10-phenantroline-type ligands (**L1**, **L2**, **L3**, **L4**) offered the best solution, with the use of bathophenantroline (**L4**) in tBuOH affording **1** in very good yield (84%). These reaction conditions were used with bromobenzene but the cross-coupling failed (8% of product and no reaction with PhCl). As it was the case for the copper source, the presence of a ligand was necessary to obtain satisfying results, as attested by the yields obtained from PhI (6–8%) in its absence (Table 2). In addition, it proved difficult to establish a relationship between the structure or the solubility of the ligand and the reactivity observed, even for the same structural family.

Next, the scope of the reaction with respect to various aryl iodides and deoxybenzoin derivatives was investigated. Two scenarios were observed, depending on the nature of the aryl iodide substituents.

In the case of electron-rich aryl iodides bearing one or two electron-donating groups (Me or OMe), a simple tuning of the copper catalytic system allowed us to obtain numerous  $\alpha$ -arylated deoxybenzoins in good to excellent yields upon

isolation (Table 3). Although the **L4**/*t*BuOH system used for 4-iodotoluene (Table 2) was applicable to all the substrates tested, improved conversions were obtained using the **L1**/1,4-dioxane couple highlighted in our preliminary studies (Table 3, entries 3, 10, 13, 14, and 16–18). The ligand **L1** (cheaper than **L4**) was also found to be efficient in combination with *t*BuOH for some examples (Table 3, entries 5, 7, and 9). In the case of *ortho*-substituted aryl iodides, which are traditionally poor substrates in copper-catalyzed arylation of C, N, and O nucleophiles, low to fair amounts of the α-arylated products were obtained.

Electron-poor aryl iodides were then considered and reacted with several deoxybenzoin derivatives (Table 4, entries 1–14). Note that for  $\alpha$ -arylation catalytic systems based on other metals than copper, this case has been less explored than those of electron-rich aryl halides. Applying the conditions of Table 3 led to poor yields of the coupling products. For example, only 37% of the  $\alpha$ -arylated compound 23 (see Table 4, entry 1 for structure) was obtained using the standard system CuI/L4/tBuOH with 4-iodofluorobenzene (the main by-product was the result of the homocoupling of deoxybenzoin). However, a simple optimization led to an increase in the yield to 52 % by using the  $\beta$ -acetylcyclohexanone ligand (L8) in tBuOH at 110°C (reaction conditions previously employed for the α-arylation from 4iodotoluene). Finally the selectivity was improved by lowering the reaction temperature to 70°C, thus producing 23 in 75% yield (Table 4, entry 1). By using these reaction conditions, 15 differently substituted arylated deoxybenzoine derivatives were obtained (Table 4) with yields ranging from low (Table 4, entry 13) to excellent (Table 4, entry 14). In some cases, the final compounds feature one or two halides (Br, Cl, F) on the aromatic rings, available for further functionalization at the corresponding positions.

The scope of this methodology was demonstrated by its simple and efficient application to the synthesis of Tamoxifen (TAM). Marketed under the trade name Nolvadex, this molecule has for a long time been the world's most commonly administrated drug for management of breast cancer. [15b,16]

We considered two new and original routes for the total synthesis of this molecule, which belongs to the triphenylethylene class of compounds. In the first pathway, the synthesis starts with the copper-catalyzed α-arylation of deoxybenzoin with 4-Iodophenol (Scheme 1, Route A). The latter is a suitable substrate as evidenced by the good yield obtained for the α-arylated deoxybenzoin derivative 37. For this step the most efficient catalytic system was CuI/L8. tBuOH was preferred over 1,4-dioxane because of the greater solubility of the phenolic reagent in alcohols. Compound 37 then underwent an alkylation/elimination/isomerization<sup>[17]</sup> sequence and the resulting intermediate 38 was directly reacted with 2-chloro-N,N-dimethylethylamine to give tamoxifen in an overall yield of 70% (over 4 steps) upon isolation.

**Table 3:** Copper-catalyzed  $\alpha$ -arylation of deoxybenzoin derivatives by aryl iodides substituted by electron-donating groups. [a]

Entry	Product	9 91	Yield	Fntry	Product		Yield
	Troduct		[%] <sup>[b]</sup>		Troduct		[%] <sup>[b]</sup>
1	Ph O Ph	1	84 <sup>[c]</sup>	12	MeO Ph	12	60 <sup>[c]</sup>
2	Ph Ph	2	99 <sup>[c]</sup>	13	-√Ph	13	89 <sup>[e]</sup>
3	Ph O Ph	3	48 <sup>[d,e]</sup>	14	Ph	14	99 <sup>[e]</sup>
4	Ph O Ph	4	99 <sup>[c]</sup>	15	Ph	15	37 <sup>[d,e]</sup>
5	MeO-Ph	5	74 <sup>[f]</sup>	16	Ph	16	99 <sup>[e]</sup>
6	Ph Ph MeO	6	75 <sup>[c]</sup>	17	MeO-\begin{picture}() \\ \Ph \\ \\ \Ph \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\	17	71 <sup>[e]</sup>
7	Ph OMe	7	51 <sup>[f]</sup>	18	CI O Ph	18	74 <sup>[e]</sup>
8	PhO	8	70 <sup>[c]</sup>	19	CI Ph OMe	19	56 <sup>[e]</sup>
9	PhO	9	56 <sup>[f]</sup>	20	Ph F	20	94 <sup>[c]</sup>
10	Ph	10	21 <sup>[d,e]</sup>	21	Br	21	81 <sup>[d,c]</sup>
11	PhO	11	88 <sup>[c]</sup>	22	PhOCI	22	99 <sup>[c]</sup>

[a] Reactions performed on 1 mmol scale (ketone/Arl: 1.5/1). [b] Yield of isolated product. [c] tBuOH/L4. [d] Yields determined by <sup>1</sup>H NMR spectroscopy. [e] 1,4-Dioxane/L1. [f] tBuOH/L1.

**Table 4:** Copper-catalyzed  $\alpha$ -arylation of deoxybenzoin derivatives by aryl iodides substituted by electron-withdrawing groups<sup>[a]</sup>

EWG = electron-withdrawing group

			3 3,-				
Entry	Product		Yield [%] <sup>[b]</sup>	Entry	Product		Yield [%] <sup>[b]</sup>
1	Ph Ph	23	75	8	F <sub>3</sub> C	30	40 <sup>[c]</sup>
2	Br—Ph Ph	24	60	9	CI Ph	31	90
3	F <sub>3</sub> C Ph	25	57	10	CI O Ph	32	75
4	F Ph O Ph	26	48	11	F <sub>3</sub> C Ph	33	33
5	F <sub>3</sub> C Ph O	27	60	12	CI Ph	34	49
6	F-Ph-O	28	57 <sup>[c]</sup>	13	CI Ph	35	17
7	Ph O	29	54 <sup>[c]</sup>	14	Ph O CI	36	99

[a] Reactions performed in tBuOH (1 mL) at 70 °C with 1 mmol of iodoarene, 1.5 mmol of ketone, 2 mmol of  $Cs_2CO_3$ , 0.1 mmol of Cul and 0.1 mmol of L8. [b] Yield of isolated product. [c] Reaction performed at 90 °C.

We also developed a second route based on a reverse strategy involving, in the first step, the iodoarene already substituted by the dimethylethylamino substituent present on tamoxifen (Scheme 1, Route B).<sup>[18]</sup> This electron-donating group proved to be a suitable substituent. The coupling of the corresponding aryl iodide with deoxybenzoin gave the expected α-arylated intermediate 39 in good yield. For this step the most efficient catalyst system was L1/CuI (10 mol %) in 1,4-dioxane. The same alkylation/elimination/isomerization sequence was used for 39 to yield tamoxifen in a satisfying 63 % (3 steps). These two synthetic pathways show that our method is easily applicable for the synthesis of major targets and that it could constitute an efficient tool for the synthesis of a library of tamoxifen derivatives.



**Scheme 1.** a) Cul (10 mol%), **L8** (10 mol%), Cs<sub>2</sub>CO<sub>3</sub> (4 equiv), tBuOH, 70 °C, 24 h; b) 1. EtMgBr (3 equiv), THF, 25 °C, 5 h, 2. HCl (37%), MeOH, 65 °C, 15 h, 3. tBuOK (4 equiv), DMSO, 50 °C, 2 h; c) NaH (3 equiv), ClC<sub>2</sub>H<sub>4</sub>NMe<sub>2</sub> (2 equiv), DMF, 50 °C, 3 h. d) Cul (10 mol%), **L1** (10 mol%), Cs<sub>2</sub>CO<sub>3</sub> (4 equiv), dioxane, 110 °C, 24 h. e) 1. EtMgBr (3 equiv), THF, 25 °C, 5 h, 2. HCl (37%), MeOH, 65 °C, 15 h, 3. tBuOK (5 equiv), DMSO, 50 °C, 2 h.

In conclusion, we have discovered the first efficient method in which the direct  $\alpha$ -arylation with simple aryl iodides of a non-activated or nonprotected family of enolizable ketones (the deoxybenzoin derivatives) is possible by using a copper catalyst system. The method is selective towards other halides (Br, Cl or F) thus allowing further functionalization of aromatic cycles without any protection/ deprotection sequence. This method is complementary to the palladium systems which catalyze the reaction using aryl chlorides. The use of copper in association with commercially available and inexpensive phenanthroline or diketone-type ligands is an advantage in line with sustainable development.[14] Finally this method demonstrated its potential in the easy and step-economical synthesis of tamoxifen, the most commonly administrated drug for treatment of breast cancer. Work is in progress to generalize its application field, to understand the mechanism, [19] and to develop an asymmetric version.

Received: July 27, 2012 Revised: September 12, 2012 Published online: November 9, 2012

**Keywords:** arenes  $\cdot$  copper  $\cdot$  homogeneous catalysis  $\cdot$  ketones  $\cdot$  synthetic methods

- M. F. Semmelhack, B. P. Chong, R. D. Stauffer, T. D. Rogerson, A. Chong, L. D. Jones, J. Am. Chem. Soc. 1975, 97, 2507.
- [2] a) T. Satoh, Y. Kawamura, M. Miura, M. Nomura, Angew. Chem. 1997, 109, 1820; Angew. Chem. Int. Ed. Engl. 1997, 36, 1740.
- [3] M. Palucki, S. L. Buchwald, J. Am. Chem. Soc. 1997, 119, 11108.
- [4] B. C. Hamann, J. F. Hartwig, J. Am. Chem. Soc. **1997**, 119, 12382.
- [5] See for example (non exhaustive list): a) M. Kawatsura, J. F. Hartwig, J. Am. Chem. Soc. 1999, 121, 1473; b) A. Ehrentraut, A. Zapf, M. Beller, Adv. Synth. Catal. 2002, 344, 209; c) F. Churruca,

- R. SanMartin, I. Tellitu, E. Dominguez, *Org. Lett.* **2002**, *4*, 1591; d) G. Adjabeng, T. Brenstrum, C. S. Frampton, A. J. Robertson, J. Hilhouse, J. McNulty, A. Capretta, *J. Org. Chem.* **2004**, *69*, 5082; e) G. A. Grasa, T. J. Colacot, *Org. Lett.* **2007**, *9*, 5489; f) M. R. Biscoe, S. L. Buchwald, *Org. Lett.* **2009**, *11*, 1773.
- [6] M. S. Viciu, R. F. Germaneau, S. P. Nolan, Org. Lett. 2002, 4, 4053.
- [7] V. Lavallo, Y. Canac, C. Prasang, B. Donnadieu, G. Bertrand, Angew. Chem. 2005, 117, 5851; Angew. Chem. Int. Ed. 2005, 44, 5705.
- [8] F. Bellina, R. Rossi, Chem. Rev. 2010, 110, 1082.
- [9] C. C. Carin Johansson, T. J. Colacot, Angew. Chem. 2010, 122, 686; Angew. Chem. Int. Ed. 2010, 49, 676.
- [10] K. D. Hesp, R. J. Lundgren, M. Stradiotto, J. Am. Chem. Soc. 2011, 133, 5194.
- [11] L. Ackermann, V. P. Mehta, Chem. Eur. J. 2012, 18, 10230.
- [12] For reviews on the catalytic Ullmann reaction see for ex: a) G. Evano, N. Blanchard, M. Toumi, Chem. Rev. 2008, 108, 3054; b) F. Monnier, M. Taillefer, Angew. Chem. 2009, 121, 7088; Angew. Chem. Int. Ed. 2009, 48, 6954. For results from our group on copper-catalyzed C-C, C-N, or C-O bond formation, see for example: c) M. Taillefer, H. J. Cristau, P. P. Cellier, J.-F. Spindler, Fr 16547-WO 0353225, 2001; d) H. J. Cristau, P. P. Cellier, J. F. Spindler, M. Taillefer, Chem. Eur. J. 2004, 10, 5607; e) H.-J. Cristau, A. Ouali, J.-F. Spindler, M. Taillefer, Chem. Eur. J. 2005, 11, 2483; f) A. Ouali, R. Laurent, A.-M. Caminade, J.-P. Majoral, M. Taillefer, J. Am. Chem. Soc. 2006, 128, 15990; g) M. Taillefer, N. Xia, A. Ouali, Angew. Chem. 2007, 119, 952; Angew. Chem. Int. Ed. 2007, 46, 934; h) N. Xia, M. Taillefer, Angew. Chem. 2009, 121, 343; Angew. Chem. Int. Ed. 2009, 48, 337; i) A. Tlili, N. Xia, F. Monnier, M. Taillefer, Angew. Chem. 2009, 121, 8881; Angew. Chem. Int. Ed. 2009, 48, 8725; j) H. Kaddouri, V. Vicente, A. Ouali, F. Ouazzani, M. Taillefer, Angew. Chem. 2009, 121, 339; Angew. Chem. Int. Ed. 2009, 48, 333; k) E. Racine, F. Monnier, J.-P. Vors, M. Taillefer, Org. Lett. 2011, 13, 2818; l) A. Tlili, F. Monnier, M. Taillefer, Chem. Commun. 2012, 48, 6408.
- For the synthesis of  $\alpha$ -arylketones the copper has been involved from other substrates than simple ketones or aryl halides. See for example the copper-catalyzed arylation/decarbonylation of diketones (one equivalent of KOAc is released and lost): a) C. He, S. Guo, L. Huang, A. Lei, J. Am. Chem. Soc. 2010, 132, 8273. 21% of a phenylated deoxybenzoin has been observed in an isolated example involving a copper system: b) S. L. Buchwald, A. Klapars, J. C. Antilla, G. E. Job, M. Wolter, F. Y. Kwong, G. Nordmann, E. J. Hennessy, US 7,115,784B2, 2006. The reaction between diaryliodonium (one equivalent of aryl is lost) and silylketene imides or silylketene acetals in the presence of chiral copper bisoxazoline catalysts has also been reported. See: c) J. S. Harvey, S. P. Simonovich, C. R. Jamison, D. W. C. MacMillan, J. Am. Chem. Soc. 2011, 133, 13782; d) A. Bigot, A. E. Williamson, M. J. Gaunt, J. Am. Chem. Soc. 2011, 133, 13778. Note that this type of reaction is also known for metal-free conditions employing diaryliodonium triflates and either cyclic silyl enol ethers or cyclic ketones, in racemic or enantioselective versions. See respectively: e) K. Chen, G. F. Koser, J. Org. Chem. 1991, 56, 5764; f) V. K. Aggarwal, B. Olofsson, Angew. Chem. 2005, 117, 5652; Angew. Chem. Int. Ed. 2005, 44, 5516. The coppercatalyzed  $\alpha$ -arylation of highly activated carbonyl compounds such as keto esters, malonic acid derivatives, or diketone is also known. See for example [8,12a-d] or g) X. Xie, G. Cai, D. Ma, Org. Lett. 2005, 7, 4693.
- [14] The results presented in this communication are protected as a patent, M. Taillefer, A. Tlili, F. Monnier, G. Danoun, FR 1255275, 2012.
- [15] a) V. Lubczyk, H. Bachmann, R. Gust, J. Med. Chem. 2002, 45, 5358; b) V. C. Jordan, Nat. Rev. Drug Discovery 2003, 2, 205; c) H.-Q. Li, Y. Luo, R. Song, Z.-L. Li, T. Yan, H.-L. Zhu,

ChemMedChem 2010, 5, 1117; d) H.-Q. Li, Y. Luo, R. Song, Z.-L. Li, T. Yan, H.-L. Zhu, ChemMedChem 2010, 5, 1110; e) H.-Q. Li, Y. Luo, P.-C. Lv, L. Shi, C.-H. Liu, H.-L. Zhu, Bioorg. Med. Chem. Lett. 2010, 20, 2025; f) T.-M. Lu, D.-H. Kuo, H.-H. Ko, L.-T. Ng, J. Agric. Food Chem. 2010, 58, 10027.

- [16] a) M. Baum, Lancet 1985, 1, 836; b) L. J. Lerner, V. C. Jordan, Cancer Res. 1990, 50, 4177; c) H. Kuramochi, J. Med. Chem. 1996, 39, 2877; d) V. C. Jordan, Br. J. Pharmacol. 2006, 147, S269.
- [17] The alkylation, performed in the presence of an ethyl magnesium Grignard reagent, leads to the corresponding tertiary alcohol. The elimination is realized under acidic conditions (HCl 37% in MeOH) to give two types of alkenes (two chemically different protons are present at the  $\alpha$  position of C-OH). After isomerization of the latter by addition of tBuOK in DMSO, the intermediate 38 is obtained with the unsaturation (Z/E = 1:1) at the required position for the tamoxifen. For more details of this sequence, see the Supporting Information.

- [18] Preparation of the aryl iodide: Z. Zhou, T.S. Corbitt, A. Parthasarathy, Y. Tang, L. K. Ista, K. S. Schanze, D. G. Whitten, J. Phys. Chem. Lett. 2010, 1, 3207.
- [19] For a recent review on the mechanism of the modern version of the Ullmann reaction see: E. Sperotto, G. P. M. van Klink, G. van Koten, J. G. de Vries, Dalton Trans. 2010, 39, 10338.